Reprogramming the solid tumor microenvironment to unlock
the full potential of cancer immunotherapy

Lever Bio develops innovative cancer therapies that reprogram the tumor microenvironment and enhance T-cell function, making immunotherapies more effective in patients who do not respond. Their business model involves licensing or selling their pipeline to major pharmaceutical companies, focusing on patients resistant to current treatments.

https://www.leverbio.com/

Date of investment May, 2025

Offices Turin